Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survivalin Patients with StageIIIc Ovarian Cancer

Q4 Medicine 武汉大学学报(医学版) Pub Date : 2015-01-01 DOI:10.14188/J.1671-8852.2015.04.015

LU Yula

{"title":"Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survivalin Patients with StageIIIc Ovarian Cancer","authors":"LU Yula","doi":"10.14188/J.1671-8852.2015.04.015","DOIUrl":null,"url":null,"abstract":"Objective:To evaluate the clinical efficacy and perioperative safety of cytoreductive surgery(CRS)in conjunction with hyperthermic intraperitonealchemotherapy(HIPEC)for treating patients with stage Ⅲc ovarian cancer.Methods:A total of 50 stage Ⅲc ovarian cancer patients were divided into the CRS(n=30),and the CRS + HIPEC group(n=24).The primary end point was overall survival(OS)and the second end points were serious adverse events(SAE).Results:The median follow-up was 44.1 months(6to 168 months)in CRS Group and 42.6months(10.5to 110.9 months)in CRS + HIPEC Group.The median OS was 27.1 months(95%CI,21.8-35.3 months)in CRS Group and 32.6 months(95%CI,24.8-40.6 months)in CRS + HIPEC Group(P0.05).Within 30 days after the surgery,SAE occurred in 3of the 30 patients in CRS Group,and in 5of the 24 patients in CRS+HIPEC Group(P=0.466).Multivariate analysis revealed that CRS + HIPEC,operation satisfaction,and chemotherapy over sixcycles were the independent factors for OS improvement.Conclusion:The CRS+HIPEC method improves the OS of stageⅢ c ovarian cancer patients,suggesting an acceptable safety.","PeriodicalId":35402,"journal":{"name":"武汉大学学报(医学版)","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"武汉大学学报(医学版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14188/J.1671-8852.2015.04.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Objective:To evaluate the clinical efficacy and perioperative safety of cytoreductive surgery(CRS)in conjunction with hyperthermic intraperitonealchemotherapy(HIPEC)for treating patients with stage Ⅲc ovarian cancer.Methods:A total of 50 stage Ⅲc ovarian cancer patients were divided into the CRS(n=30),and the CRS + HIPEC group(n=24).The primary end point was overall survival(OS)and the second end points were serious adverse events(SAE).Results:The median follow-up was 44.1 months(6to 168 months)in CRS Group and 42.6months(10.5to 110.9 months)in CRS + HIPEC Group.The median OS was 27.1 months(95%CI,21.8-35.3 months)in CRS Group and 32.6 months(95%CI,24.8-40.6 months)in CRS + HIPEC Group(P0.05).Within 30 days after the surgery,SAE occurred in 3of the 30 patients in CRS Group,and in 5of the 24 patients in CRS+HIPEC Group(P=0.466).Multivariate analysis revealed that CRS + HIPEC,operation satisfaction,and chemotherapy over sixcycles were the independent factors for OS improvement.Conclusion:The CRS+HIPEC method improves the OS of stageⅢ c ovarian cancer patients,suggesting an acceptable safety.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

细胞减少手术加腹腔内高温化疗可提高ii期卵巢癌患者的生存率

目的:评价细胞减少术(CRS)联合腹腔热化疗(HIPEC)治疗Ⅲc期卵巢癌的临床疗效和围手术期安全性。方法:将50例Ⅲc期卵巢癌患者分为CRS组(n=30)和CRS + HIPEC组(n=24)。主要终点是总生存期(OS)，第二个终点是严重不良事件(SAE)。结果:CRS组中位随访时间为44.1个月(6 ~ 168个月)，CRS + HIPEC组中位随访时间为42.6个月(10.5 ~ 110.9个月)。CRS组的中位OS为27.1个月(95%CI,21.8 ~ 35.3个月)，CRS + HIPEC组的中位OS为32.6个月(95%CI,24.8 ~ 40.6个月)(P0.05)。CRS组30例患者中有3例术后30天发生SAE, CRS+HIPEC组24例患者中有5例术后30天发生SAE (P=0.466)。多因素分析显示，CRS + HIPEC、手术满意度和化疗时间超过6个周期是OS改善的独立因素。结论:CRS+HIPEC方法可改善Ⅲc期卵巢癌患者的OS，安全性可接受。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊